Effect of Metformin on Visual Function in Patients With Glaucoma

Status Recruiting

Clinical Trial Summary

The purpose of this study is to determine whether Metformin could prevent the progression of glaucoma in a safe and effective manner.

Clinical Trial Description

Primary open-angle glaucoma (POAG) is a serious blinding disease characterized by irreversible damage to retinal ganglion cells (RGCs). At present, there is no effective treatment for the rescue of visual function loss caused by POAG. Metformin is the classic first-line therapy for diabetes. Recently, it has been found that Metformin may have other beneficial effects such as promoting weight loss and reversing age-related neurodegeneration. Importantly, retrospective case-control studies found that there were associations between Metformin treatment and a reduction in the incidence of glaucoma. Specifically, diabetic patients treated by Metformin had a 25% lower risk to develop open-angle glaucoma. In addition, previous animal experiments have preliminarily shown that Metformin can play a neuroprotective role by activating AMPK kinase, regulating methylation levels and promoting ganglion cell survival. Therefore, the investigators hypothesize that Metformin can prevent visual function deterioration via rescuing retinal ganglion cells. The main objective of this study is to assess the progression of visual field loss in patients with POAG after treatment with Metformin versus placebo. The secondary objectives include the followings: RNFL thickness, vision, cup/disk ratio, safety, and biochemical tests to determine the alteration of AMPK and methylation parameters associated to the use of Metformin. Approximately 40 study subjects will be randomized in a 1:1 ratio to each treatment group. The treatment group will be assigned to the study intervention (oral Metformin) for 12 months while the placebo group will receive placebo containing fructose and starch for 12 months. Throughout the 12-month study period, progression of visual function and systematic safety examinations will be measured. At 18 months, there will be one additional follow up visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04155164
Study type	Interventional
Source	Zhongshan Ophthalmic Center, Sun Yat-sen University
Contact	Xialin Liu, Prof.
Phone	(020)66610720
Email	liuxialin@gzzoc.com
Status	Recruiting
Phase	N/A
Start date	December 10, 2019
Completion date	May 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05564091` - Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma	N/A
Recruiting	`NCT02792803` - A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma	Phase 4
Terminated	`NCT02801617` - Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension	Phase 3
Completed	`NCT01384149` - EXTERNAL SLT Treatment in Patients With Uncontrolled OPEN ANGLE GLAUCOMA	Phase 1
Completed	`NCT00300079` - Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension	Phase 4
Enrolling by invitation	`NCT00221923` - African Descent and Glaucoma Evaluation Study
Recruiting	`NCT05605743` - Alternate Nostril Breathing Training in Geriatrics With Glaucoma and High Blood Pressure	N/A
Completed	`NCT04828057` - Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Completed	`NCT01442896` - STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk
Enrolling by invitation	`NCT05557721` - Uddevalla Skövde Transscleral Micropulse Study
Recruiting	`NCT04595227` - Glaucoma Screening Using Dynamic Analysis of Computerized Pupillary Light Reflex Assessment Device
Terminated	`NCT04141865` - Effect of Xen Implantation on the Aqueous Humor Proteome
Completed	`NCT01979913` - An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More	Phase 4
Completed	`NCT01943721` - A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension	Phase 1
Completed	`NCT02023242` - Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes	N/A
Not yet recruiting	`NCT01711177` - Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma	N/A
Completed	`NCT01769521` - Relationship Between 24-hour IOP Pattern and the 24-hour Blood Pressure Pattern in Patients With POAG	N/A
Recruiting	`NCT00773123` - Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma.	N/A
Recruiting	`NCT00773877` - Comparison of Retinal Nerve Fiber Layer (RNFL) Thickness Measurements by Time-Domain and Spectral-Domain OCT In Glaucoma Patients	N/A
Completed	`NCT02544646` - Changes in Ocular Rigidity After Trabeculectomy in Patients With POAG	N/A